# A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

> **NCT06360211** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 15 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer
- EGFR Mutation
- HER2 Mutation
- Healthy Volunteers

## Interventions

- **DRUG:** BAY2927088
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT06360211
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-17
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360211, "A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06360211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*